Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
about
mTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling AxisBreast cancer chemoprevention: old and new approachesTwo distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.IL4 receptor ILR4α regulates metastatic colonization by mammary tumors through multiple signaling pathwaysCombination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinomaMammalian target of rapamycin complex 2 (mTORC2) is a critical determinant of bladder cancer invasionPrevention of carcinogen and inflammation-induced dermal cancer by oral rapamycin includes reducing genetic damageThe miR-491-3p/mTORC2/FOXO1 regulatory loop modulates chemo-sensitivity in human tongue cancer.Single-nucleotide polymorphism in microRNA-binding site of SULF1 target gene as a protective factor against the susceptibility to breast cancer: a case-control study.The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2.OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivoNew and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus.Competitive but Not Allosteric mTOR Kinase Inhibition Enhances Tumor Cell Radiosensitivity.Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.A viral kinase mimics S6 kinase to enhance cell proliferation.Intrinsic cellular signaling mechanisms determine the sensitivity of cancer cells to virus-induced apoptosis.Involvement of Rictor/mTORC2 in cardiomyocyte differentiation of mouse embryonic stem cells in vitro.mTOR pathway in colorectal cancer: an update.RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR.STAT3 inhibitors: finding a home in lymphoma and leukemia.Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies.Mammalian target of rapamycin (mTOR) complex 2 regulates filamin A-dependent focal adhesion dynamics and cell migration.DNA damage-induced S and G2/M cell cycle arrest requires mTORC2-dependent regulation of Chk1.Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.Effects of mTOR Inhibitors on Components of the Salvador-Warts-Hippo Pathway.mTORC1 and -2 Coordinate Transcriptional and Translational Reprogramming in Resistance to DNA Damage and Replicative Stress in Breast Cancer Cells.Catalytic mammalian target of rapamycin inhibitors as antineoplastic agents.Rictor/mammalian target of rapamycin complex 2 promotes macrophage activation and kidney fibrosis.The role of RICTOR downstream of receptor tyrosine kinase in cancers.The role of FSH and TGF-β superfamily in follicle atresia.Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival.
P2860
Q27310985-FDE2139F-70E4-4EB9-ABCB-B799011342BFQ27693259-3A4934AD-85E6-4D27-977B-7652DB27D47BQ33859205-C61C7207-F790-4157-A31A-77DD66135231Q34052636-C3E0F502-FB09-4F2B-8BF7-307B36662BEBQ34977124-ECAE11D1-2102-4D91-80EE-D971E0ED504FQ35060424-DAAA0EFE-00B8-4C76-8A67-E7C407A1DFAAQ35563024-EDD6F9C5-148C-4C16-AD50-8F6F0B81ECFAQ35740111-B7DFFE90-BB49-45CD-BF8C-330BA11499B8Q36044425-D0D9A5E4-9402-4208-8954-899AAB91C4FCQ36123027-8C631E36-1D10-48F5-B72E-5819CA14CC38Q36413415-13A37F5C-A71D-47C4-9740-8FAF403DF9DCQ36547566-4DBB9CA5-CE61-465D-8363-C015DA323A57Q36865078-A848DBCE-C574-4985-AFF8-EA8A116D911CQ36899877-B9198A1B-AEFD-4382-B525-A32D32C0257AQ37102331-2689B0B2-7A55-4A24-B8C0-63A62F2D48E2Q37416907-18F668B9-4136-4427-8F06-39BC7675860FQ37604612-AFA005C9-1549-4256-96FE-A7D9732AD1BFQ37649634-E6795261-8559-48CE-A3C5-1E016686F1C0Q37701523-84AF3BCB-3338-4489-9C49-DF9B15D350E2Q38202556-E7D463F0-8B2C-436F-9489-458C2C9F610BQ38212951-A0E2A5BA-DE79-4331-9008-28F4411F4CC3Q38779779-ED241B9F-C21D-4957-A4C7-5AD254EB7D51Q38933652-ED7AD57F-1AD4-42A5-9541-FF01CC6DA30AQ41457277-66B79D41-C146-454D-B753-FCD36105B3BBQ41889585-11A41577-9099-48DA-B049-A8B0DC68A305Q42321289-05A8BEDC-55D5-4FF9-BA7F-4E6F1B0C3BFEQ48101340-4CAE62E2-A4B4-44C8-B8D2-1380CF8F14A5Q48323884-822EA594-0BA1-43FD-A7A3-AC811B484EE1Q49887908-366760C9-D33E-4700-83F8-165322B081F9Q51766047-3BDC24B0-EE7E-4F4A-AC5E-12FD00642DE6Q52390750-7FB38979-01BA-4876-8DE2-04E19B661F45
P2860
Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
@en
Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
@nl
type
label
Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
@en
Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
@nl
prefLabel
Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
@en
Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
@nl
P2093
P2860
P1476
Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer
@en
P2093
Anling Liu
Chunhong Jia
Cuilan Yang
Guangyu Yao
Hang Zheng
Liping Wang
Xiaokai Wang
P2860
P2888
P304
P356
10.1007/S10549-012-2036-2
P407
P50
P577
2012-04-04T00:00:00Z